Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
- Status
- COMPLETED
- Phase
- PHASE2
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years
- Status
- COMPLETED
- Phase
- PHASE3
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
- Status
- COMPLETED
- Phase
- PHASE2
Pre Operative Trastuzumab in Operable Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
- Status
- TERMINATED
- Phase
- PHASE2
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
- Status
- COMPLETED
- Phase
- PHASE3
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE3
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
- Status
- COMPLETED
- Phase
- PHASE2
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
- Status
- TERMINATED
- Phase
- PHASE1
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
- Status
- TERMINATED
- Phase
- PHASE2
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
GRN1005 for Brain Metastases From Breast or Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2